# A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Source: https://onco.cc/trials/nct05884398/  
OnCo record `nct05884398` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC is a phase 3 interventional study registered as NCT05884398 by Janssen Research & Development, LLC, with 420 participants enrolled, started 2023-08-31 and due to reach its primary completion in 2026-10-12. Interventions recorded: Apalutamide, Androgen-deprivation Therapy (ADT). Conditions listed: Metastatic Castrate-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05884398
- Phase: 3
- Setting: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT05884398: https://clinicaltrials.gov/study/NCT05884398

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Apalutamide](https://onco.cc/drugs/apalutamide/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct05884398.json